$XBI $127 -1%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$NVAX -2% Novavax Statement on Participation in Mix-and-Match COVID-19 Vaccine Booster Trial in the United Kingdom. source
$AZN -1% AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan. source
Pipeline Updates
$MCRB -2% SERES THERAPEUTICS PRESENTS DATA ACROSS ITS BROAD MICROBIOME PIPELINE INCLUDING NEW 24-WEEK DATA FROM SER-109 PHASE 3 ECOSPOR III STUDY IN RECURRENT C. DIFFICILE INFECTION AT DIGESTIVE DISEASE WEEK 2021. source
$HALO -1% Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®. source
$VIR +1% EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19. source
$ATNX -1% Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp. source
$RYTM +1% Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency. source
$RYTM +1% Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency. source
$ALBO +5% Albireo Receives Positive CHMP Opinion for Bylvay™ (odevixibat) for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC). source
$MYOV +3% Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids. source
$ANVS +125% ANNOVIS BIO ANNOUNCES POSITIVE PHASE 2 DATA – ANVS401 IMPROVES COGNITION IN ALZHEIMER’S DISEASE - PATIENTS’ COGNITION IMPROVED 3.3 POINTS ON ADAS-COG11. source
$BLUE +2% bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD). source
$ONTX -16% Onconova Therapeutics Announces The Initial Dosing Of The First Patient In The U.S. Phase 1 Clinical Trial Of ON 123300. source
Finance Updates
$VBIV +0% VBI Vaccines Announces $12 Million Second Tranche of Debt Financing with K2 HealthVentures. source
Posted by DV